These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 39129397)
1. Natural compounds from herbs and nutraceuticals as glycogen synthase kinase-3β inhibitors in Alzheimer's disease treatment. Zhao Z; Yuan Y; Li S; Wang X; Yang X CNS Neurosci Ther; 2024 Aug; 30(8):e14885. PubMed ID: 39129397 [TBL] [Abstract][Full Text] [Related]
2. Isoorientin, a GSK-3β inhibitor, rescues synaptic dysfunction, spatial memory deficits and attenuates pathological progression in APP/PS1 model mice. Tan X; Liang Z; Li Y; Zhi Y; Yi L; Bai S; Forest KH; Nichols RA; Dong Y; Li QX Behav Brain Res; 2021 Feb; 398():112968. PubMed ID: 33069740 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease. Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466 [TBL] [Abstract][Full Text] [Related]
4. Stereoisomers of Schisandrin B Are Potent ATP Competitive GSK-3β Inhibitors with Neuroprotective Effects against Alzheimer's Disease: Stereochemistry and Biological Activity. Hu XL; Guo C; Hou JQ; Feng JH; Zhang XQ; Xiong F; Ye WC; Wang H ACS Chem Neurosci; 2019 Feb; 10(2):996-1007. PubMed ID: 29944335 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic implications of glycogen synthase kinase-3β in Alzheimer's disease: a novel therapeutic target. Mandlik DS; Mandlik SK; S A Int J Neurosci; 2024 Jun; 134(6):603-619. PubMed ID: 36178363 [TBL] [Abstract][Full Text] [Related]
6. Impact of GSK-3β and CK-1δ on Wnt signaling pathway in alzheimer disease: A dual target approach. Sharma V; Chander Sharma P; Reang J; Yadav V; Kumar Tonk R; Majeed J; Sharma K Bioorg Chem; 2024 Jun; 147():107378. PubMed ID: 38643562 [TBL] [Abstract][Full Text] [Related]
7. Discovery of novel quinolin-2-one derivatives as potential GSK-3β inhibitors for treatment of Alzheimer's disease: Pharmacophore-based design, preliminary SAR, in vitro and in vivo biological evaluation. Abdo Moustafa E; Abdelrasheed Allam H; Fouad MA; El Kerdawy AM; Nasser Eid El-Sayed N; Wagner C; Abdel-Aziz HA; Abdel Fattah Ezzat M Bioorg Chem; 2024 May; 146():107324. PubMed ID: 38569322 [TBL] [Abstract][Full Text] [Related]
8. Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3β Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New C-Glycosylflavones. Liang Z; Li QX ACS Chem Neurosci; 2018 May; 9(5):1166-1183. PubMed ID: 29381861 [TBL] [Abstract][Full Text] [Related]
9. Human tau accumulation promotes glycogen synthase kinase-3β acetylation and thus upregulates the kinase: A vicious cycle in Alzheimer neurodegeneration. Zhou Q; Li S; Li M; Ke D; Wang Q; Yang Y; Liu GP; Wang XC; Liu E; Wang JZ EBioMedicine; 2022 Apr; 78():103970. PubMed ID: 35339896 [TBL] [Abstract][Full Text] [Related]
10. Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer's therapy. Sai Varshini M; Aishwarya Reddy R; Thaggikuppe Krishnamurthy P J Drug Target; 2024 Sep; 32(8):909-917. PubMed ID: 38838023 [TBL] [Abstract][Full Text] [Related]
11. The protective underlying mechanisms of Schisandrin on SH-SY5Y cell model of Alzheimer's disease. Zhao ZY; Zhang YQ; Zhang YH; Wei XZ; Wang H; Zhang M; Yang ZJ; Zhang CH J Toxicol Environ Health A; 2019; 82(19):1019-1026. PubMed ID: 31739764 [TBL] [Abstract][Full Text] [Related]
12. The Key Roles of GSK-3β in Regulating Mitochondrial Activity. Yang K; Chen Z; Gao J; Shi W; Li L; Jiang S; Hu H; Liu Z; Xu D; Wu L Cell Physiol Biochem; 2017; 44(4):1445-1459. PubMed ID: 29190615 [TBL] [Abstract][Full Text] [Related]
13. Could protein phosphatase 2A and glycogen synthase kinase-3 beta be targeted by natural compounds to ameliorate Alzheimer's pathologies? Manoharan SD; Abdul Hamid H; Md Hashim NF; Cheema MS; Chiroma SM; Mustapha M; Mehat MZ Brain Res; 2024 Apr; 1829():148793. PubMed ID: 38309553 [TBL] [Abstract][Full Text] [Related]
14. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link. Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of thieno[3,2- Yan N; Shi XL; Tang LQ; Wang DF; Li X; Liu C; Liu ZP J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1724-1736. PubMed ID: 35698879 [TBL] [Abstract][Full Text] [Related]
16. Design, Bio-evaluation and Molecular Dynamics Simulation of Novel GSK-3β Inhibitors. Lyu W; Li Q; Li Q; Chen Y; Wang Y; Tang T; Feng F; Chi H; Li Y; Liu W; Sun H Mol Inform; 2021 Dec; 40(12):e2060031. PubMed ID: 34323388 [TBL] [Abstract][Full Text] [Related]
17. Tolfenamic acid inhibits GSK-3β and PP2A mediated tau hyperphosphorylation in Alzheimer's disease models. Zhang H; Wang X; Xu P; Ji X; Chi T; Liu P; Zou L J Physiol Sci; 2020 Jun; 70(1):29. PubMed ID: 32517647 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of thieno[3,2-c]pyrazol-3-amine derivatives as potent glycogen synthase kinase 3β inhibitors for Alzheimer's disease. Yan N; Xie F; Tang LQ; Wang DF; Li X; Liu C; Liu ZP Bioorg Chem; 2023 Sep; 138():106663. PubMed ID: 37329814 [TBL] [Abstract][Full Text] [Related]
19. Rosmarinic Acid Derivatives' Inhibition of Glycogen Synthase Kinase-3β Is the Pharmacological Basis of Kangen-Karyu in Alzheimer's Disease. Paudel P; Seong SH; Zhou Y; Park CH; Yokozawa T; Jung HA; Choi JS Molecules; 2018 Nov; 23(11):. PubMed ID: 30413117 [TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents. Wang M; Liu T; Chen S; Wu M; Han J; Li Z Eur J Med Chem; 2021 Jan; 209():112874. PubMed ID: 33017743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]